Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2011-04-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT00921531
- Locations
- 🇨🇳
Liver Cancer Institute, Shanghai, Shanghai, China
Induction Chemotherapy With Nimotuzumab in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- Interventions
- Drug: PF regimen (cisplatin and 5-FU)
- First Posted Date
- 2009-05-29
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT00910117
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Study of Exemestane After Anastrozole or Letrozole Treatment of Postmenopausal Women With Hormone Responsive Breast Cancer
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2009-05-15
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 540
- Registration Number
- NCT00902954
- Locations
- 🇨🇳
Jinsong Lu, Shanghai, Shanghai, China
Safety and Efficacy of Hypothermia to Treat Neonatal Hypoxic-Ischemic Encephalopathy
Phase 3
Completed
- Conditions
- Hypoxic-Ischemic Encephalopathy
- Interventions
- Device: Cooling cap (YJW608-04B)
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2009-05-28
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 256
- Registration Number
- NCT00890409
- Locations
- 🇨🇳
Children's Hospital, Fudan University, Shanghai, Shanghai, China
Preoperative Transhepatic Arterial Chemotherapy (TAC) in the Treatment of Liver Metastasis of Resectable Colorectal Cancer
Phase 4
- Conditions
- Colorectal Cancer
- Interventions
- Drug: tac + folfox4Drug: folfox4
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2009-04-02
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT00874406
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Oxaliplatine Based Adjuvant Chemotherapy for Stage II/III Colorectal Cancer: 8 Cycles Versus 12 Cycles
Phase 4
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Drug: 12 cycles of oxaliplatine based adjuvant chemotherapyDrug: 8 cycles of oxaliplatine based adjuvant chemotherapy
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 400
- Registration Number
- NCT00868816
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal Cancer
Phase 4
Completed
- Conditions
- Unresectable Liver Metastasis of Colorectal Cancer
- Interventions
- Procedure: Folfox4Procedure: tac + folfox4
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT00869271
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal Cancer
Phase 4
- Conditions
- Liver MetastasisColorectal Cancer
- Interventions
- Procedure: TACE + folfox 4Procedure: TAC + folfox4
- First Posted Date
- 2009-03-25
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 200
- Registration Number
- NCT00868569
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 40
- Registration Number
- NCT00854425
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
Comparison Study of Doxorubicin Versus Epirubicin-induced Cardiotoxicity in Patients With DLBCL
Phase 3
Completed
- Conditions
- Lymphoma
- Interventions
- Drug: CEOP regimenDrug: CHOP regimen
- First Posted Date
- 2009-03-03
- Last Posted Date
- 2014-08-20
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 398
- Registration Number
- NCT00854568
- Locations
- 🇨🇳
Fudan University Cancer Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath